What is ChromaCode?
ChromaCode operates at the intersection of biotechnology and data analytics, providing a robust HDPCR multiplexing platform that transforms how laboratories approach genomic testing. By simplifying complex molecular profiling, the company enables physicians and researchers to access actionable data with greater speed and affordability than traditional methods. Its core value proposition lies in its ability to deliver high-margin, rapid-turnaround diagnostic solutions, which are essential for modern oncology and disease monitoring. As a key player in the diagnostic landscape, ChromaCode's technology is designed to be highly customizable, allowing for seamless integration into existing lab workflows while maintaining rigorous standards for accuracy and clinical utility.
How much funding has ChromaCode raised?
ChromaCode has raised a total of $50M across 2 funding rounds:
Series B
$12M
Series C
$38M
Series B (2017): $12M with participation from Domain Associates and New Enterprise Associates
Series C (2020): $38M led by California Institute of Technology, Windham Ventures, Domain Associates, Moore Venture Partners, New Enterprise Associates, Adjuvant Capital, Northpond Ventures, and Okapi Venture Capital
Key Investors in ChromaCode
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. It manages nine subsequent biotech venture capital funds and has a total of $2.8 billion in assets.
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates (NEA) is a venture capital firm focused on helping entrepreneurs build businesses.
Moore Venture Partners
Founded in 2010, Moore Venture Partners (MVP) is a traditional venture capital firm that focuses on investing in early, growth, and expansion-stage technology and life science companies.
What's next for ChromaCode?
Looking ahead, ChromaCode is poised to leverage its recent capital to expand its footprint in the precision medicine market. The strategic focus remains on scaling the adoption of its HDPCR assays, which are increasingly vital for tumor profiling and complex disease diagnostics. By continuing to refine its data analysis capabilities, the company aims to solidify its position as a leader in the genomic solutions space. Future growth will likely be driven by deeper penetration into clinical diagnostic markets and the development of new, high-throughput assays that address the evolving needs of healthcare providers and patients seeking more precise, data-driven health outcomes.
See full ChromaCode company page
